Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | 3204-4464 Markham St VICTORIA BC V8Z 7X8 |
Tel: | N/A |
Website: | https://www.ipatherapeutics.com |
IR: | See website |
Key People | ||
Mitch Levine Chairman of the Board | Jennifer Lynne Bath President, Chief Executive Officer, Director | Kristin Taylor Interim Chief Financial Officer |
Ilse Roodink Chief Scientific Officer | Kari Graber Vice President - Commercial Services |
Business Overview |
ImmunoPrecise Antibodies Ltd. is a Canada-based biotherapeutic research and technology company. It leverages systems biology, multiomics modelling and artificial intelligence systems to support its technologies in bioplatform-based antibody discovery. Its services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners to discover and develop novel biologics. It utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases. It offers services, such as immunogen design and manufacturing, B cell sorting incorporating its function-first B cell screening and sequencing, and the production and screening of custom, immune, and naive phage display libraries. It also operates LSA instrument platform, which is a provider of high-throughput large and small molecule screening and characterization solutions. |
Financial Overview |
For the nine months ended 31 January 2024, Immunoprecise Antibodies Ltd revenues increased 20% to C$18.1M. Net loss decreased 57% to C$9.1M. Revenues reflect Project revenue segment increase from C$4.8M to C$11.3M, Product sales revenue segment increase from C$363K to C$972K, Antibody production segment increase of 10% to C$5.7M, Europe segment increase from C$1.9M to C$8M, United States of America segment increase from C$3M to C$9M. |
Employees: | 102 as of Apr 30, 2023 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $40.57M as of Jan 31, 2024 |
Annual revenue (TTM): | $17.45M as of Jan 31, 2024 |
EBITDA (TTM): | -$7.73M as of Jan 31, 2024 |
Net annual income (TTM): | -$10.51M as of Jan 31, 2024 |
Free cash flow (TTM): | -$3.37M as of Jan 31, 2024 |
Net Debt Last Fiscal Year: | $6.03M as of Jan 31, 2024 |
Shares outstanding: | 26,315,260 as of Jan 31, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |